News
JSPR
20.40
-3.68%
-0.78
Buy Rating Affirmed: Jasper Therapeutics’ Briquilimab Shows Promising Outlook in Chronic Urticaria Treatment Market
TipRanks · 3d ago
Weekly Report: what happened at JSPR last week (0415-0419)?
Weekly Report · 5d ago
Weekly Report: what happened at JSPR last week (0408-0412)?
Weekly Report · 04/15 11:48
Weekly Report: what happened at JSPR last week (0401-0405)?
Weekly Report · 04/08 11:54
Jasper Therapeutics Initiated at Outperform by Evercore ISI Group
Dow Jones · 04/03 11:44
Jasper Therapeutics Price Target Announced at $65.00/Share by Evercore ISI Group
Dow Jones · 04/03 11:44
Evercore ISI Group Initiates Coverage On Jasper Therapeutics with Outperform Rating, Announces Price Target of $65
Benzinga · 04/03 11:34
JASPER THERAPEUTICS INC <JSPR.O>: EVERCORE ISI INITIATES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $65
Reuters · 04/03 11:26
Weekly Report: what happened at JSPR last week (0325-0329)?
Weekly Report · 04/01 11:51
RBC starts Jasper Therapeutics at outperform, cites market opportunity
Healthcare RBC starts Jasper Therapeutics at outperform, cites market opportunity. RBC Capital Markets cites the company's potential to access the $100B+ mast cell disease market. Jasper's lead asset, briquilimab, could be a "franchise builder" for the company.
Seeking Alpha · 03/28 20:03
Jasper Therapeutics Initiated at Outperform by RBC Capital
Dow Jones · 03/28 08:46
Jasper Therapeutics Price Target Announced at $70.00/Share by RBC Capital
Dow Jones · 03/28 08:46
RBC Capital Initiates Coverage On Jasper Therapeutics with Outperform Rating, Announces Price Target of $70
Benzinga · 03/28 08:36
Weekly Report: what happened at JSPR last week (0318-0322)?
Weekly Report · 03/25 11:55
Jasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
Jasper Therapeutics, Inc. Management will participate in a fireside chat at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference on March 28, 2024. Jasper is a biotechnology company focused on development of briquilimab, a novel antibody therapy.
Barchart · 03/21 15:30
Buy Rating Affirmed for Jasper Therapeutics as Briquilimab Shows Market Potential in Chronic Urticaria Treatment
TipRanks · 03/20 13:05
Analysts’ Top Healthcare Picks: Jasper Therapeutics (JSPR), Alphatec Holdings (ATEC)
TipRanks · 03/20 13:00
Jasper Therapeutics Announces First Patient Dosed In Phase 1b/2a SPOTLIGHT Clinical Study Of Briquilimab In Chronic Inducible Urticaria
First patient has been dosed in Jasper's Phase 1b/2a clinical study of briquilimab for the treatment of chronic spontaneous urticaria. Jasper is focused on development of a novel antibody therapy targeting c-Kit in mast cell driven diseases. The company anticipates reporting preliminary data from the SPOTLIGHT study in the second half of 2024.
Benzinga · 03/19 12:05
Jasper Therapeutics Initiated at Outperform by TD Cowen
Dow Jones · 03/18 12:44
TD Cowen Initiates Coverage On Jasper Therapeutics with Outperform Rating
Benzinga · 03/18 12:34
More
Webull provides a variety of real-time JSPR stock news. You can receive the latest news about Jasper Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About JSPR
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting mast cell driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU). It also has ongoing programs in diseases where targeting diseased hemopoietic stem cells can provide benefits, such as Lower to Intermediate Risk Myelodysplastic Syndrome (LR-MDS), and stem cell transplant conditioning regimens. The Company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. The SCF/c-Kit pathway is a survival signal for mast cells. It is also developing briquilimab as a one-time conditioning therapy for severe combined immunodeficiency (SCID) patients undergoing a second stem cell transplant for which it is conducting a Phase 1/2 clinical trial.